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response measure at 6 mos was predictive of subsequent OS
(p ¼ 0.007) and FFS (p¼0.004). Patient-reported changes
were associated with FFS after 3 mos but not with other
outcomes. No response measures predicted NRM. The fact
that FFS could be predicted by clinician- or patient-reported
response measures might reﬂect that clinicians and patients
control the main determinant of FFS, i.e., whether new sys-
temic immunosuppression is added. Incorporation of the
calculated CR + PR category did not signiﬁcantly change the
ability of the clinician-reported CR + PR to predict FFS or
survival after 6 months. We conclude that clinician-reported
CR+PR is highly associated with OS after 6 months, which is
independent of calculated CR+PR. Calculated response algo-
rithms might be improved by understanding and incorpo-
rating clinician judgment in assessing response.44
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Invariant natural killer T (iNKT) cells are potent regulators
of immune responses in humans (TCRa Va24-Ja18) and mice
(TCRa Va14-Ja18). We showed previously that host and
donor iNKT cells play a critical role for graft-versus-host
disease (GVHD) prevention and tolerance induction
following allogeneic hematopoietic cell transplantation
(HCT). In this study, we explored the role of adoptively
transferred third party CD4+ iNKT cells in a murine model of
allogeneic HCT across major histocompatibility barriers.
After 8 Gy total body irradiation BALB/c (H-2Kd) recipient
mice were transplanted with T cell-depleted bone marrowFigure 1. Representative bioluminescence images of BALB/c mice that
received Tcon alone or Tcon together with adoptively transferred third party
CD4+ iNKT cells. Tcon derived from FoxP3DTR/GFP/luc C57BL/6 mice with the
expression of the luciferase gene being under the control of the FoxP3
promoter.together with 1x106 CD4+/CD8+ T cells (Tcon) from C57BL/6
(H-2Kb) donor mice. Adoptive transfer of sorted (purity
>95%) 5x104 CD4+ iNKT cells from FVB/N (H2-Kq) third party
mice signiﬁcantly improved survival (p<0.001) while
retaining Tcon mediated graft-versus-tumor (GVT) effects
against BCL1 and A20 lymphoma cells (p¼0.002). Notably,
CD4+ iNKT cells from third party mice were as protective as
CD4+ iNKT cells from donor mice (p¼0.50). Consistently,
weight and GVHD scores improved in mice that received a
single injection of third party CD4+ iNKT cells as compared to
animals that received Tcon alone. Bioluminescence from
expanding luciferase expressing alloreactive Tcon was
signiﬁcantly decreased while showing a Th2-biased cytokine
proﬁle in animals treated with third party CD4+ iNKT cells
(p¼0.003). Interestingly, inhibition of Tcon proliferation
was comparable to animals that received CD4+ iNKT cells
from donor mice (p¼0.90). Although we found that third
party CD4+ iNKT cells were rejected by day +10 after allo-
geneic HCT, adoptive transfer resulted in a robust expan-
sion of luciferase expressing donor Treg using C57BL/6
FoxP3DTR/GFP/luc mice as a source of Tcon (p¼0.006, Figure 1).
Depletion of Treg from the graft by injection of diphtheria
toxin abrogated both donor Treg expansion and protection
from GVHD lethality through third party CD4+ iNKT cells. In
conclusion, low numbers of puriﬁed and adoptively trans-
ferred thirdparty CD4+ iNKTcells protect fromGVHD lethality
through activation and expansion of donor Tregwith retained
GVT effects. Despite the fact that iNKT cells are a rare cell
population, the in vivo activity of small numbers of cells and
feasibility of in vitro expansion provide the basis for clinical
translation.45
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Members of the sialic acid binding Igelike lectin (Siglec)
family, such as Siglec-G, have immunoreceptor tyrosine-
based inhibitory motifs (ITIM) regions that negatively
regulate innate immune activation induced by non-
infectious damage-associated molecular patterns (DAMPs).
The T-cell autonomous role of Siglec-G in modulating
immunity is not known. In order to examine the role of
Siglec-G on T cells we utilized the well-established MHC
disparate B6->BALB/c model of allogeneic BMT. BALB/c WT
mice were lethally irradiated (850cGy) and transplanted
on day 0 with 5x106 WT bone marrow from either
syngeneic WT-BALB/c or allogeneic WT-B6 along with
0.5x106CD90+T cells from WT or Siglec-G-/- B6 animals. The
allogeneic recipients receiving donor T cells from Siglec-G-/-
animals showed signiﬁcantly more severe GVHD and worse
survival compared to allogeneic WT-B6 animals (p¼0.01).
This increased mortality was also associated with greater
